180 related articles for article (PubMed ID: 34930435)
1. Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report.
Takami T; Yasuda K; Uozumi N; Musiake Y; Shintani H; Kataoka N; Yamaguchi T; Makimoto S
J Med Case Rep; 2021 Dec; 15(1):604. PubMed ID: 34930435
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Peritoneal Metastasis from an Unresectable Advanced Gastric Cancer with a Good Response to Nivolumab].
Kumano T; Shibata R; Ota A; Tanaka S; Komatsu S; Imura K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2424-2426. PubMed ID: 33468982
[TBL] [Abstract][Full Text] [Related]
3. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.
Matsumoto R; Arigami T; Matsushita D; Okubo K; Tanaka T; Yanagita S; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Ohtsuka T
World J Surg Oncol; 2020 Jul; 18(1):179. PubMed ID: 32693806
[TBL] [Abstract][Full Text] [Related]
4. [Brain Metastasis Arising from Gastric Cancer during Long-Term Treatment Using Nivolumab].
Namikawa T; Marui A; Yokota K; Kawanishi Y; Munekage M; Uemura S; Maeda H; Kitagawa H; Nagata Y; Kobayashi M; Hanazaki K
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1544-1546. PubMed ID: 36733129
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab.
Namikawa T; Ishida N; Tsuda S; Fujisawa K; Munekage E; Iwabu J; Munekage M; Uemura S; Tsujii S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Case Rep; 2018 Jul; 4(1):71. PubMed ID: 29978335
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
7. [Long-Term Survival of an Adolescent and Young Adult Patient with Unresectable Advanced Gastric Cancer in Whom Multidisciplinary Treatment Was Effective].
Namikawa T; Utsunomiya M; Yokota K; Kawanishi Y; Yamaguchi S; Munekage M; Maeda H; Kitagawa H; Nagata Y; Kobayashi M; Hanazaki K; Seo S
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1985-1987. PubMed ID: 38303273
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Recurrent Gastric Cancer with Long-Term Control via Two Resections and Multidisciplinary Treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract][Full Text] [Related]
9. Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report.
Komo T; Suzuki T; Tazawa H; Sada H; Morimoto H; Shimada N; Hadano N; Onoe T; Sudo T; Shimizu Y; Tashiro H
Int J Surg Case Rep; 2021 Jul; 84():106161. PubMed ID: 34237686
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.
Dai P; Rao X; Zhang X; Qiu E; Wu G; Lin Y; Li S; Li Z; Cai Z; Han S
Front Immunol; 2022; 13():908558. PubMed ID: 35844567
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.
Ishido K; Tanabe S; Katada C; Ishibashi Y; Kitahara G; Onoue M; Kubota Y; Furue Y; Wada T; Watanabe A; Kusano C
J Gastrointest Cancer; 2023 Jun; 54(2):485-491. PubMed ID: 35437632
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Initially Unresectable Advanced Gastric Cancer Radically Resected by Conversion Surgery after Nivolumab Immunotherapy].
Koizumi N; Kashiwagi S; Ogino S; Kamada Y; Fujiki H; Sakakura C
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1624-1626. PubMed ID: 33268741
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer.
Jun C; Yamauchi S; Yube Y; Egawa H; Yoshimoto Y; Kubota A; Tsuda K; Kaji S; Orita H; Oka S; Mine S; Fukunaga T
Surg Case Rep; 2023 May; 9(1):86. PubMed ID: 37204618
[TBL] [Abstract][Full Text] [Related]
15. Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy.
Watanabe H; Fujikawa H; Komori K; Kano K; Takahashi K; Yamada T; Inokuchi Y; Machida N; Yokose T; Rino Y; Masuda M; Ogata T; Oshima T
Case Rep Gastroenterol; 2021; 15(2):562-567. PubMed ID: 34616257
[TBL] [Abstract][Full Text] [Related]
16. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.
Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H
Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777
[TBL] [Abstract][Full Text] [Related]
17. [Experience with Nivolumab in the Treatment of Metastatic Gastric Cancer].
Takao C; Matsuhashi N; Murase Y; Yasufuku I; Tanahashi T; Yamaguchi K; Matsui S; Imai H; Tanaka Y; Takahashi T; Yoshida K
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1546-1548. PubMed ID: 30382073
[TBL] [Abstract][Full Text] [Related]
18. Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report.
Arigami T; Matsushita D; Okubo K; Tanaka T; Sasaki K; Noda M; Kita Y; Mori S; Tsuruda Y; Kurahara H; Ohtsuka T
Surg Case Rep; 2020 Oct; 6(1):271. PubMed ID: 33074364
[TBL] [Abstract][Full Text] [Related]
19. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
20. Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer.
Sato Y; Yamashita H; Kobayashi Y; Nagaoka K; Hisayoshi T; Kawahara T; Kuroda A; Saito N; Iwata R; Okumura Y; Yagi K; Aiko S; Nomura S; Kakimi K; Seto Y
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
